Your browser is no longer supported. Please, upgrade your browser.
OPKO Health, Inc.
Index- P/E87.29 EPS (ttm)0.05 Insider Own1.40% Shs Outstand640.76M Perf Week-5.20%
Market Cap2.76B Forward P/E45.54 EPS next Y0.09 Insider Trans21.81% Shs Float401.33M Perf Month-20.49%
Income30.60M PEG7.27 EPS next Q0.05 Inst Own29.10% Short Float24.28% Perf Quarter-1.87%
Sales1.44B P/S1.92 EPS this Y109.00% Inst Trans-3.58% Short Ratio11.89 Perf Half Y33.44%
Book/sh2.61 P/B1.61 EPS next Y-26.98% ROA1.30% Target Price- Perf Year152.41%
Cash/sh0.11 P/C38.19 EPS next 5Y12.00% ROE1.90% 52W Range1.12 - 6.47 Perf YTD6.08%
Dividend- P/FCF475.44 EPS past 5Y22.70% ROI2.10% 52W High-35.24% Beta1.84
Dividend %- Quick Ratio1.00 Sales past 5Y23.90% Gross Margin37.70% 52W Low275.08% ATR0.41
Employees5269 Current Ratio1.40 Sales Q/Q120.60% Oper. Margin4.00% RSI (14)34.95 Volatility6.43% 6.72%
OptionableYes Debt/Eq0.15 EPS Q/Q127.90% Profit Margin2.10% Rel Volume1.54 Prev Close4.32
ShortableYes LT Debt/Eq0.14 EarningsFeb 18 AMC Payout0.00% Avg Volume8.20M Price4.19
Recom1.80 SMA20-17.61% SMA50-12.53% SMA2002.41% Volume12,639,744 Change-3.01%
Nov-25-19Initiated Piper Jaffray Overweight $2.50
Mar-02-18Downgrade JP Morgan Neutral → Underweight
Sep-14-17Downgrade JP Morgan Overweight → Neutral
Jun-21-16Reiterated Standpoint Research Buy $16 → $18
Jun-03-16Initiated Standpoint Research Buy $16
Mar-31-16Reiterated Barrington Research Outperform $17 → $16
Oct-16-15Initiated JP Morgan Overweight $14
Sep-11-15Downgrade Jefferies Buy → Hold
Mar-03-15Downgrade Oppenheimer Outperform → Perform
May-12-14Reiterated Oppenheimer Outperform $13 → $12
Mar-14-14Initiated Oppenheimer Outperform $13
Nov-13-13Reiterated Ladenburg Thalmann Buy $10 → $14.50
May-30-13Reiterated Ladenburg Thalmann Buy $8.50 → $10
Oct-22-12Initiated Barrington Research Outperform $6
Dec-01-11Reiterated Ladenburg Thalmann Buy $6 → $8.50
Jul-14-11Initiated Ladenburg Thalmann Buy $6
Feb-22-21 11:51AM  
Feb-19-21 06:14AM  
Feb-18-21 04:38PM  
Feb-17-21 10:11AM  
Feb-03-21 09:01AM  
Jan-28-21 08:00AM  
Jan-26-21 08:30AM  
Jan-25-21 06:07AM  
Jan-14-21 09:46AM  
Jan-13-21 03:40PM  
Jan-07-21 05:45PM  
Jan-06-21 07:11AM  
Jan-05-21 08:00AM  
Jan-04-21 12:05PM  
Dec-31-20 08:30AM  
Dec-21-20 08:00AM  
Dec-18-20 09:40AM  
Dec-12-20 11:18AM  
Dec-10-20 02:39AM  
Dec-02-20 04:06PM  
Nov-20-20 04:45PM  
Nov-13-20 10:30AM  
Nov-12-20 06:30PM  
Nov-11-20 09:11AM  
Nov-10-20 11:25AM  
Nov-06-20 07:07AM  
Nov-04-20 09:09AM  
Nov-02-20 10:41AM  
Oct-30-20 12:18PM  
Oct-29-20 07:25PM  
Oct-27-20 10:36AM  
Oct-23-20 05:45PM  
Oct-22-20 12:33PM  
Oct-21-20 07:20AM  
Oct-20-20 08:00AM  
Oct-18-20 08:12AM  
Oct-17-20 07:09AM  
Oct-16-20 05:45PM  
Oct-14-20 10:04AM  
Oct-13-20 12:51PM  
Oct-12-20 06:06AM  
Oct-09-20 08:00AM  
Oct-08-20 09:08AM  
Oct-07-20 05:45PM  
Oct-05-20 02:07PM  
Oct-01-20 03:30PM  
Sep-30-20 08:43AM  
Sep-28-20 05:45PM  
Sep-25-20 11:30AM  
Sep-22-20 05:45PM  
Sep-16-20 09:25AM  
Sep-15-20 05:45PM  
Sep-09-20 11:30AM  
Sep-08-20 03:58PM  
Sep-03-20 09:17AM  
Sep-02-20 04:05PM  
Sep-01-20 03:55PM  
Aug-29-20 11:32AM  
Aug-27-20 12:39PM  
Aug-25-20 09:13AM  
Aug-24-20 12:40PM  
Aug-17-20 08:54AM  
Aug-14-20 11:12AM  
Aug-13-20 08:06AM  
Aug-12-20 12:04PM  
Aug-10-20 08:17AM  
Aug-07-20 11:30AM  
Aug-06-20 08:00AM  
Aug-05-20 03:35PM  
Aug-03-20 01:40PM  
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FROST PHILLIP MD ET ALCEO & ChairmanFeb 19Buy4.77500,0002,383,455191,871,694Feb 22 07:37 AM
Fishel Robert ScottDirectorJan 25Option Exercise2.7060,000162,20060,000Jan 26 04:07 PM
FROST PHILLIP MD ET ALCEO & ChairmanDec 28Buy4.00300,0001,199,500191,371,694Dec 29 07:33 AM
FROST PHILLIP MD ET ALCEO & ChairmanNov 09Buy3.18250,000794,669191,071,694Nov 10 06:53 AM
FROST PHILLIP MD ET ALCEO & ChairmanOct 30Buy3.45600,0002,072,820190,821,694Nov 02 06:57 AM
Rubin Steven DExecutive VP-AdministrationAug 26Buy3.9910,00039,9436,167,732Aug 27 08:40 AM
FROST PHILLIP MD ET ALCEO & ChairmanJun 03Buy2.27100,000227,000190,221,694Jun 04 07:26 AM
FROST PHILLIP MD ET ALCEO & ChairmanJun 02Buy2.42100,000242,410190,121,694Jun 03 07:54 AM
FROST PHILLIP MD ET ALCEO & ChairmanMay 28Buy2.16100,000215,975190,021,694May 29 07:21 AM
FROST PHILLIP MD ET ALCEO & ChairmanMay 26Buy2.35250,000587,986189,921,694May 27 08:03 AM
FROST PHILLIP MD ET ALCEO & ChairmanMay 07Buy2.08400,000831,606189,671,694May 08 07:45 AM
FROST PHILLIP MD ET ALCEO & ChairmanApr 17Buy1.66325,000540,364189,271,694Apr 20 08:06 AM
FROST PHILLIP MD ET ALCEO & ChairmanApr 16Buy1.6325,00040,738188,946,694Apr 17 08:02 AM
FROST PHILLIP MD ET ALCEO & ChairmanApr 15Buy1.55200,000309,377188,921,694Apr 16 08:20 AM
FROST PHILLIP MD ET ALCEO & ChairmanApr 07Buy1.28400,000510,984188,721,694Apr 08 08:02 AM
FROST PHILLIP MD ET ALCEO & ChairmanApr 03Buy1.1550,00057,592188,321,694Apr 06 08:18 AM
FROST PHILLIP MD ET ALCEO & ChairmanApr 02Buy1.16500,000581,185188,271,694Apr 03 07:41 AM
FROST PHILLIP MD ET ALCEO & ChairmanApr 01Buy1.23643,549793,012187,771,694Apr 02 08:12 AM
FROST PHILLIP MD ET ALCEO & ChairmanMar 30Buy1.35161,968218,037187,128,145Mar 31 08:06 AM
FROST PHILLIP MD ET ALCEO & ChairmanMar 27Buy1.40100,000139,976186,966,177Mar 30 08:00 AM
FROST PHILLIP MD ET ALCEO & ChairmanMar 26Buy1.38200,000275,445186,866,177Mar 27 08:01 AM
FROST PHILLIP MD ET ALCEO & ChairmanMar 19Buy1.49100,000148,871186,666,177Mar 20 07:44 AM
Japour Anthony JDirectorMar 12Buy1.515007551,000Mar 13 06:03 AM
FROST PHILLIP MD ET ALCEO & ChairmanMar 10Buy1.61300,000481,636186,566,177Mar 11 09:45 AM